Compositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis

Patent metadata

Field	Value
Publication number	US-12263196-B2
Application number	US-202318490521-A
Country	US
Kind code	B2
Filing date	Oct 19, 2023
Priority date	Apr 10, 2021
Publication date	Apr 1, 2025
Grant date	Apr 1, 2025

Abstract

A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

First claim

What is claimed is:

1. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis comprising:
administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-3 and a pharmaceutically acceptable carrier,
wherein the Siphoviridae bacteriophage Bac-FRP-3 is deposited in the Korean Collection for Type Culture (KCTC) under accession number KCTC 14401BP and has an ability to lyse the enterotoxigenic Bacteroides fragilis cells and the genome sequence as set forth in SEQ ID NO: 1,
wherein the Siphoviridae bacteriophage Bac-FRP-3 has a latent period of 10-100 minutes and a burst size of 1000-2100 plaque-forming units (PFU)/infected cell,
wherein the Siphoviridae bacteriophage Bac-FRP-3 has structural proteins in the size of approximately 25 kDa, 48 kDa, 68 kDa, 75 kDa, 117 kDa, and 245 kDa; and
wherein the composition has a concentration of Siphoviridae bacteriophage Bac-FRP-3 of 1× 10 4 pfu/ml to 1×10 15 pfu/ml or 1×10 4 pfu/g to 1×10 15 pfu/g.

2. The method of claim 1 , wherein the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

3. The method of claim 1 , wherein the composition further contains one or more selected from the group consisting of a lubricant, a wetting agent, a sweetener, a flavor, an emulsifier, a suspending agent, and a preservative.

4. The method of claim 1 , wherein the infection or disease is acute or chronic intestinal disease, selected from the group consisting of diarrhea, colitis and colonic neoplasia, bacteremia, and colorectal cancer.

5. The method of claim 1 , wherein the composition is a solution, suspension, emulsion in oil, water-soluble medium, extract, powder, granule, tablet, or capsule.

Assignees

• Intron Biotechnology Inc

Inventors

• Yoon Seong Jun
• Son Jee Soo
• Kim In Hwang
• Paik Hyoung Rok
• Oh Eun Kyoung
• Jun Soo Youn
• Kang Sang Hyeon

Classifications

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C12N2795/10321

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2795/10332

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title